CureVac rethinks lead cancer program after posting PD-1 data, limiting future studies to mRNA vaccine combos

CureVac is rethinking development of immunity activator CV8102 in the wake of the publication of data from a checkpoint inhibitor combination trial, vowing to only consider further clinical studies if the drug candidate is paired with “a defined mRNA cancer vaccine.”